RNTX Rein Therapeutics, Inc.
$0.70▲ +21.43%
Healthcare
Other
After hours
$0.70▼ -0.60%
Oct 27, 5:39 PM ET
Volume 620.3K
Avg Volume (10D) 512.6K
Key Metrics & Fundamentals
Market Cap
$60.75M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.54 - 2.18
% vs 50 MA
-6.32%
% vs 200 MA
-32.63%
RSI-14
51.0
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.16
Free Cash Flow
-$8.64M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$6.08M
COGS
–
Operating Exp
$6.08M
Operating Income
-$6.08M
EBIT
-$6.08M
Pretax Income
-$6.38M
Net Income
-$6.38M
EPS (Diluted)
-0.10
Price & Volume History
Loading chart…
Recent News
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
GlobeNewswire · Sep 4, 2026 8:00 AM ET
Rein Therapeutics to Present at Upcoming September Investor Conferences
GlobeNewswire · Sep 3, 2026 4:01 PM ET
Here's Why You Should Add RNTX Stock to Your Portfolio Now
Zacks · Sep 3, 2026 11:01 AM ET
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
GlobeNewswire · Aug 20, 2026 8:00 AM ET
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 14, 2026 6:44 AM ET
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
GlobeNewswire · Aug 4, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See RNTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.